Scholars@Duke
Rani Bansal

Rani Bansal

Assistant Professor of Medicine
Medicine, Medical Oncology
rani.bansal@duke.edu
4101 Macon Pond, Raleigh, NC 27607

Selected Publications

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.

Journal Article Breast Cancer Res Treat · December 2025 PURPOSE: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), inc ... Full text Link to item Cite

A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.

Journal Article Commun Med (Lond) · August 5, 2025 BACKGROUND: The Dallas Metastatic Cancer Study is a clinical database established to examine local trends associated with the diagnosis and treatment of de novo metastatic breast cancer and identify factors for further evaluation. Clinical characteristics ... Full text Link to item Cite

Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.

Journal Article Cancer · May 15, 2025 PURPOSE: Improvements in systemic therapy have resulted in significant heterogeneity in survival outcomes for metastatic breast cancer patients. As such, recently proposed staging guidelines for de novo metastatic breast cancer stratify patients into four ... Full text Link to item Cite

Genomic and transcriptomic landscape of HER2-low breast cancer.

Journal Article Breast Cancer Res Treat · January 2025 BACKGROUND: Novel agents have expanded the traditional HER2 definitions to include HER2-Low (HER2L) Breast Cancer (BC). We sought to evaluate the distinct molecular characteristics of HER2L BC to understand potential clinical/biologic factors driving resis ... Full text Link to item Cite

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Journal Article Commun Med (Lond) · December 2, 2024 BACKGROUND: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these "cold tumors". In clinica ... Full text Link to item Cite

Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.

Journal Article JCO Precis Oncol · December 2024 PURPOSE: Malignant phyllodes tumors (MPTs) are rare fibroepithelial tumors of the breast with aggressive biologic behavior and high recurrence rates. Surgery remains the primary treatment modality for these tumors; however, initial investigations suggest a ... Full text Link to item Cite

Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.

Journal Article Journal of Clinical Oncology · June 10, 2024 LBA5500 Background: Extra-renal clear cell cancer (CCC) are rare tumors that can arise from any organ. Gynecologic CCC can originate from the ovaries, endometrium, or cervix. Compared to serous carcinomas, ovarian CCC is associat ... Full text Cite

Abstract PO4-24-08: Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy

Conference Cancer Research · May 2, 2024 AbstractIntroduction:Phyllodes tumors (PT) are rare fibroepithelial tumors of the breast, comprising ~1% of all breast cancers, a subset of which have considerable malignant ... Full text Cite

Abstract PO3-19-04: The CROWN STUDY: A multicenter prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor

Conference Cancer Research · May 2, 2024 AbstractBackground: Treatment for premenopausal women with high or intermediate risk hormone receptor (HR)+ breast cancer (BC) includes the concurrent use of ovarian function suppression (OFS) and an aromata ... Full text Cite

Abstract 6472: Response to PARP inhibitors in patients with breast cancer metastatic to the central nervous system

Conference Cancer Research · March 22, 2024 AbstractBackground: Central nervous system (CNS) metastasis from breast cancer can be challenging to treat due to the limited blood brain barrier penetration of many systemic therapies. PARP inhibitors (PARP ... Full text Cite

Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study.

Journal Article Am Heart J · January 2024 Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with h ... Full text Link to item Cite

Evaluating Patient Experience in a Multidisciplinary Breast Cancer Clinic: A Prospective Study.

Journal Article J Womens Health (Larchmt) · January 2024 Background: Multidisciplinary clinics (MDCs) are a care model in which patients see several physicians across specialties and/or other allied health professionals in a single appointment in a shared space. This study sought to better understand patients' e ... Full text Link to item Cite

Triple Negative Breast Cancer and Brain Metastases.

Journal Article Clin Breast Cancer · December 2023 The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metastases (BrM) during their metastatic disease course. 1 Thi ... Full text Link to item Cite

Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer

Conference Cancer Research · March 1, 2023 AbstractIntroduction: Breast cancer has pioneered precision medicine with prognostic and predictive subtypes, defined by immunohistochemistry (IHC). Novel therapeutic strategies have led to the emergence of ... Full text Cite

Ovarian Cancer: Primary Treatment and Approach to Recurrent Disease

Chapter · January 1, 2023 This chapter provides answers to practice-based questions with case studies covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of ovarian cancer. Ovarian cancer is the seventh most comm ... Full text Cite

The Stem Cell Continuum Model and Implications in Cancer

Chapter · January 1, 2022 The hematopoietic stem cell is constantly fluctuating through various intrinsic phenotypic potentials. It has dynamic plasticity and is intimately tied to cell cycle dynamics as well as numerous external stimuli. The salient studies conclude the stem cell ... Full text Cite

Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment.

Journal Article Vaccines (Basel) · June 13, 2021 Gastrointestinal (GI) malignancies are some of the most common and devastating malignancies and include colorectal, gastric, esophageal, hepatocellular, and pancreatic carcinomas, among others. Five-year survival rates for many of these malignancies remain ... Full text Link to item Cite

Targeted therapies for gastroesophageal cancers.

Journal Article Ann Transl Med · September 2020 Gastroesophageal cancers are some of the most common malignancies worldwide. A significant portion of patients are diagnosed with advanced or metastatic disease given the insidious nature of gastroesophageal cancers. In the instance where surgical resectio ... Full text Link to item Cite

Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism.

Journal Article Am J Clin Oncol · February 2020 PURPOSE: Cancer patients are at a higher risk of venous thromboembolism (VTE) than the general population. In the general population, blacks are at a higher risk of VTE compared with whites. The influence of race on cancer-associated VTE remains unexplored ... Full text Link to item Cite

Race/Ethnicity, Primary Language, and Income Are Not Demographic Drivers of Mortality in Breast Cancer Patients at a Diverse Safety Net Academic Medical Center.

Journal Article Int J Breast Cancer · 2015 Objective. To examine the impact of patient demographics on mortality in breast cancer patients receiving care at a safety net academic medical center. Patients and Methods. 1128 patients were diagnosed with breast cancer at our institution between August ... Full text Link to item Cite